Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Kairos Pharma announced positive interim efficacy data from its Phase 2 trial of ENV-105 in combination with apalutamide for metastatic prostate cancer, showing a statistically significant difference in progression-free survival.
Kairos Pharma announced positive interim efficacy data from its Phase 2 trial of ENV-105 in combination with apalutamide for metastatic prostate cancer.